IQVIA Expands Preclinical Services with Charles River Drug Discovery Asset Acquisition
IQVIA will acquire Charles River Laboratory's drug discovery assets, including its in vitro screening platforms and medicinal chemistry services. The acquisition expands IQVIA's early-stage research capabilities to capture greater preclinical services demand across North America and Europe.
1. Transaction Details
IQVIA has signed an agreement to acquire drug discovery assets from Charles River Laboratories, including in vitro screening platforms, target identification tools and medicinal chemistry units. The deal is expected to close in Q2 2026 subject to customary regulatory approvals.
2. Strategic Rationale and Impact
The acquisition bolsters IQVIA’s end-to-end preclinical services offering, enabling cross-selling opportunities to existing biopharma clients. It aims to drive revenue synergies by expanding early-stage research capabilities and strengthening IQVIA’s competitive position in the CRO market.